IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML |
|
Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER) |
|
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life |
|
antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation |
|
Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-integrin-[beta]1expression |
|
Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect |
|
Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction |
|
Das Blaue Buch: Chemotherapie-Manual Hämatologie und Onkologie |
|
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML |
|
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma |
|
Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma |
|
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors |
|
Correction: Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease |
|
Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany |
|
Current immunotherapeutic approaches in T cell non-Hodgkin lymphomas |
|
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia |
|
Development of highly sensitive digital droplet PCR for detection of cKIT mutations in circulating free DNA that mediate resistance to TKI treatment for gastrointestinal stromal tumor (GIST) |
|
Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small cell lung cancer |
|
Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma |
|
Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model |
|
First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience |
|
HIF-1[alpha] and HIF-2[alpha] differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice |
|
impact of pulmonary function in patients undergoing autologous stem cell transplantation |
|
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab |
|
Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics |
|
Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer |
|
Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia |
|
Molecular genetic characterization of individual cancer cells isolated via single-cell printing |
|
Molekulare Pathogenese der chromosomalen Translokationen in akuten Leukämien |
|
Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation |
|
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia |
|
Murine oncostatin M has opposing effects on the proliferation of OP9 bone marrow stromal cells and NIH/3T3 fibroblasts signaling through the OSMR |
|
A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance |
|
NIPA (Nuclear Interaction Partner of ALK) is crucial for effective NPM-ALK mediated lymphomagenesis |
|
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation |
|
Patient‐derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphoma |
|
Personalized clinical decision making through implementation of a molecular tumor board: a German single-center experience |
|
Personalized treatment selection and disease monitoring using circulating tumor DNA profiling in real-world cancer patient management |
|
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation - immune signature correlates with response |
|
Phosphorylation of Beclin 1 by BCR-ABL suppresses autophagy in CML |
|
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma |
|
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia |
|
Proteomic phosphosite analysis identified crucial NPM-ALK-mediated NIPA serine and threonine residues |
|
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients |
|
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) |
|
Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition |
|
SMARCC1 controls oncogenic NOTCH1 signaling in T-cell acute lymphoblastic leukemia |
|
Spleen tyrosine kinase is involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia |
|
Therapeutic targeting of endoplasmic reticulum stress in acute graft-versus-host disease |
|
TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis |
|
Zirkulierende Tumor-DNA (ctDNA) als molekularer Verlaufsparameter und prognostischer Biomarker bei Pankreaskarzinomen |
|